Advertisement
ADVANCED SEARCH

This Article Figures Only Full Text Full Text (PDF) Résumé Correction (v178,p1466) Submit a response View responses Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Katz, L. Y. Articles by Sareen, J. Search for Related Content PubMed PubMed Citation Articles by Katz, L. Y., MD Articles by Sareen, J., MD Related Collections Drugs: psychiatry Suicide Mood disorders (including depression) Child and adolescent psychiatry Related Articles

Effect of regulatory warnings on antidepressant prescription rates, use of health services and outcomes among children, adolescents and young adults

From the Department of Psychiatry (Katz, Enns, Cox, Sareen), University of Manitoba; and the Manitoba Centre for Health Policy, Department of Community Health Sciences (Kozyrskyj, Prior), University of Manitoba, Winnipeg, Man.

Correspondence to: Dr. Laurence Katz, Department of Psychiatry, University of Manitoba, Rm. PZ-162, 771 Bannatyne Ave., Winnipeg MB R3E 3N4; fax 204 787-4975; lkatz{at}hsc.mb.ca

Background: Regulatory bodies worldwide, including Health Canada, have issued warnings about prescribing antidepressants to children and adolescents. We sought to determine whether the Health Canada warning had the desired effects on prescribing patterns and outcomes and whether it had any unintended health consequences.

Methods: We examined data from prescription and health care databases representing more than 265 000 children, adolescents and young adults annually to determine changes in the rates of antidepressant prescription, use of health services and outcomes in these populations in the 9 years before and the 2 years after the Health Canada warning. We also examined the data for unintended changes in these rates among patients with anxiety disorders. We used young adults as the comparison group because they were not targeted by the warning.

Results: Following the warning, the rate of antidepressant prescriptions decreased among children and adolescents (relative risk [RR] 0.86, 95% confidence interval [CI] 0.81–0.91) and among young adults (RR 0.90, 95% CI 0.86–0.93). Ambulatory visits because of depression decreased among children and adolescents (RR 0.90, 95% CI 0.85–0.96) and young adults (RR 0.91, 95% CI 0.87–0.96). The rate of completed suicides among children and adolescents rose significantly after the warning (RR 1.25, 95% CI 1.08–1.44; annual rate per 1000 = 0.04 before and 0.15 after the warning). There was no equivalent change in the rate of completed suicides among young adults (RR 1.01, 95% CI 0.93–1.10; annual rate per 1000 = 0.15 before and 0.22 after the warning). Among patients with an anxiety disorder, the prescription rates did not change among children and adolescents, except for a decrease in the use of selective serotonin reuptake inhibitors other than fluoxetine, but the rates among young adults changed similar to the pattern of changes in the overall prescribing of antidepressants. There was also a significant decrease in the rate of physician visits because of anxiety disorders among young adults after the warning.

Interpretation: Health advisories and warnings issued by regulatory bodies may have unintended consequences on the provision of care, delivery of health services and clinical outcomes. Further efforts are required to ensure that health warnings do not result in unexpected harm.

This article has been cited by other articles:

				E. R. Dorsey, A. Rabbani, S. A. Gallagher, R. M. Conti, and G. C. Alexander Impact of FDA Black Box Advisory on Antipsychotic Medication Use Arch Intern Med, January 11, 2010; 170(1): 96 - 103. [Abstract] [Full Text] [PDF]

				A. M. Libby, H. D. Orton, and R. J. Valuck Persisting Decline in Depression Treatment After FDA Warnings Arch Gen Psychiatry, June 1, 2009; 66(6): 633 - 639. [Abstract] [Full Text] [PDF]

				H. I Weisberg, V. C Hayden, and V. P Pontes Selection criteria and generalizability within the counterfactual framework: explaining the paradox of antidepressant-induced suicidality? Clinical Trials, April 1, 2009; 6(2): 109 - 118. [Abstract] [PDF]

				K. Menon To prescribe or not to prescribe? The British Journal of Psychiatry, February 1, 2009; 194(2): 189 - 189. [Full Text] [PDF]

				L. Y. Katz MD Concerns about health care warnings and their impact on prescribing behaviour Can. Med. Assoc. J., August 26, 2008; 179(5): 405 - 406. [Full Text] [PDF]

				E. Valiyeva PhD, N. Herrmann MD, P. A. Rochon MD MPH, S. S. Gill MD MSc, and G. M. Anderson MD PhD Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis Can. Med. Assoc. J., August 26, 2008; 179(5): 438 - 446. [Abstract] [Full Text] [PDF]

				M. M. Mamdani PharmD MPH Health advisories: when good intentions go bad Can. Med. Assoc. J., April 8, 2008; 178(8): 1025 - 1026. [Full Text] [PDF]

eLetters:

HOME	CURRENT ISSUE	PAST ISSUES	COLLECTIONS	HELP	SEARCH
Copyright 1995-2008, Canadian Medical Association. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p) All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association.